Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Oppenheimer in a report released on Tuesday, Benzinga reports. They presently have a $9.00 target price on the stock. Oppenheimer's price objective would suggest a potential upside of 165.49% from the stock's current price.
A number of other brokerages have also weighed in on GANX. HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Gain Therapeutics in a research note on Monday, April 1st. Chardan Capital reiterated a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Wednesday, March 27th.
Check Out Our Latest Analysis on GANX
Gain Therapeutics Stock Performance
NASDAQ:GANX traded up $0.22 on Tuesday, hitting $3.39. The company's stock had a trading volume of 66,419 shares, compared to its average volume of 154,296. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average of $4.09 and a two-hundred day moving average of $3.45. The firm has a market capitalization of $54.99 million, a P/E ratio of -1.98 and a beta of 0.43. Gain Therapeutics has a one year low of $2.00 and a one year high of $5.65.
Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. Research analysts predict that Gain Therapeutics will post -1.17 earnings per share for the current year.
Insider Transactions at Gain Therapeutics
In related news, Director Jeffrey Scott Riley acquired 30,000 shares of the stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now directly owns 30,000 shares in the company, valued at $115,800. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.00% of the stock is owned by corporate insiders.
About Gain Therapeutics
(
Get Free Report)
Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Featured Articles
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
